Humanetics is a revenue-producing clinical-stage company located in Minneapolis, Minnesota engaged in accelerated discovery, development and commercialization of proprietary drugs, medical foods and consumer products in markets with urgent and unmet needs. Our business is segmented based on these three FDA product classifications. We are developing a platform of pharmaceutical compounds that protect healthy tissues from the damaging effects of radiation. Our lead product, BIO 300, is being developed with funding from the U.S. Department of Health and Human Services as a medical countermeasure against radiological weapons. We are also developing a unique daily oral therapy to prevent and/or slow the progression of Alzheimer’s disease.